TY - JOUR
TI - Editorial: The new trial EMPAREG-outcomes in type 2 diabetes: “and death shall have no dominion”?
AU - Papanas, N.
AU - Tsioufis, C.
AU - Maltezos, E.S.
JO - Current Vascular Pharmacology
PY - 2016
VL - 14
TODO - 4
SP - 316-318
PB - Bentham Science Publishers B.V.
SN - 1570-1611
TODO - 10.2174/1570161114999160229142200
TODO - alogliptin;  empagliflozin;  glucagon;  hemoglobin A1c;  high density lipoprotein cholesterol;  insulin glargine;  lixisenatide;  low density lipoprotein cholesterol;  saxagliptin;  sitagliptin;  antidiabetic agent;  benzhydryl derivative;  glucoside, body weight;  cardiovascular mortality;  cerebrovascular accident;  clinical trial (topic);  Editorial;  glycemic control;  heart failure;  heart infarction;  hospitalization;  human;  non insulin dependent diabetes mellitus;  outcome assessment;  systolic blood pressure;  transient ischemic attack;  waist circumference;  cardiovascular disease;  complication;  mortality;  non insulin dependent diabetes mellitus, Benzhydryl Compounds;  Cardiovascular Diseases;  Diabetes Mellitus, Type 2;  Glucosides;  Humans;  Hypoglycemic Agents
TODO - null
ER -